Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vysis prenatal genetic test gains FDA clearance; IPO proceeds to expand marketing efforts.

This article was originally published in The Gray Sheet

Executive Summary

VYSIS MARKETING OF ANEUVYSION PRENATAL GENETIC TEST should get a boost from the firm's 3.5 mil. share initial public offering. A portion of the proceeds from the proposed IPO, which is expected to bring in about $44.8 mil., is tabbed for expansion of direct sales and marketing capabilities. Downers Grove, Illinois-based Vysis announced 510(k) clearance of the Aneuvysion assay on Oct. 28; the premarket application was submitted to FDA in June.



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts